Objective. The management of postoperative pain is a major health care issue. While the cost of intravenous acetaminophen (IVA) is significantly greater than its oral acetaminophen (OA) counterpart, less is known regarding comparative effectiveness of these routes. The purpose of this study was to determine whether perioperative IVA is equivalent in reducing postoperative pain compared with perioperative OA for laparoscopic cholecystectomy (LapChole).
Methods. This study was conducted at Womack Army Medical Center (WAMC), Fort Bragg, North Carolina, between January 2013 and June 2015. Sixty-seven subjects with symptomatic cholelithiasis were randomly assigned to receive two doses (1,000 mg each) of either IVA or OA. A numerical rating scale (NRS) score of pain was obtained preoperatively and every six hours for 24 hours postoperation. The primary objective was to assess whether treatment groups had significantly different 24-hour postoperative sum of pain intensity differences (SPID24) using an analysis of covariance test.
Results. Sixty subjects completed the study and were included in the analysis. Treatment groups did not differ in SPID24, even when controlling for age, gender, and preoperative pain levels (F(1,55) 5 0.39, P 5 0.54, partial g 2 5 0.007), nor did 24-hour opioid consumption when controlling for age, gender, and operation time (F(1, 46) 5 0.47, P 5 0.50, partial g 2 5 0.01). Furthermore, treatment groups were equally as likely to report average postoperative NRS scores of 4 or higher (b 5 0.24, Exp(B) 5 1.28, P 5 0.68).
Conclusions. The results show no evidence of differences between IVA or OA in pain or opioid consumption among a sample of patients undergoing LapChole. Due to low sample size, these descriptive findings warrant larger studies, which may have a significant economic impact.
Introduction
Postsurgical pain management is a major health care issue. Up to 77% of patients report pain after surgery, with up to 80% reporting moderate-to-severe pain [1] . In addition to the pain itself, poorly controlled postoperative pain can lead to other complications such as longer hospital stays, increased time to ambulation, and decreased patient satisfaction [2, 3] . Furthermore, some data suggests that poorly controlled acute pain can lead to chronic postsurgical pain [4] .
Since the mid-1980s, laparoscopic cholecystectomy was adopted as a safe and effective alternative to traditional "open" cholecystectomy for the treatment of symptomatic gallstones, with approximately one million laparoscopic procedures in the United States per year according to national data [5] . Acute pain following a laparoscopic cholecystectomy can be complex [6] . The American Society of Anesthesiologists (ASA) published a practice guideline stating, "Whenever possible, anesthesiologists should use multimodal pain management therapy. Central regional blockade with local anesthetics should be considered and unless contraindicated, patients should receive an around-the-clock regimen of COXIBs, NSAIDs, or acetaminophen" [7] .
Opioid use for acute and chronic pain carries the risk of misuse [8] [9] [10] [11] and is associated with various side effects including postoperative altered mental status, nausea and vomiting, ileus, constipation, and respiratory depression [12] , whereas acetaminophen is relatively safe and does not carry the risk of dependence, as well as respiratory depression, ileus, or postoperative nausea or vomiting [13] . The Food and Drug Administration (FDA) approved the use of intravenous acetaminophen (IVA) for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and for the reduction of fever [14] , and prior literature has shown that IVA is effective in reducing opioid use [15, 16] . IVA reaches peak plasma concentrations faster (15-minute median time to reach peak plasma concentration [Tmax]) than its oral-administered (OA) equivalent (45-minute Tmax) and remains in the therapeutic window longer [17, 18] , though it is almost 35 times more expensive [15] . One recent study found that administration routes did not produce significantly different analgesic results [19] . Taken together, it is important to compare the effectiveness of IVA and OA in managing pain, while balancing the need to reduce health care costs.
Two studies compared IVA with OA with clinical end points; however, the administration was initiated in the postoperative period [20] or intra-operative period [21] . To our knowledge, there has been no prospective, randomized, double-blind study that compares the administration of perioperative IVA vs perioperative OA using clinical end points. In the present prospective trial, we hypothesize subjects receiving IVA will have statistically similar self-reported pain intensity differences as subjects receiving OA in the 24 hours after receiving elective laparoscopic cholecystectomy (LapChole) for symptomatic cholelithiasis.
Methods

Subject Selection and Study Design
This study was approved by the Womack Army Medical Center Institutional Review Board. Each subject voluntarily agreed to participate in the study and provided written informed consent. This trial is registered on www.ClinicalTrials.gov (NCT# NCT01823224). The present study employed a randomized, double-blind, placebo-controlled trial design to evaluate the comparative efficacy of IVA and OA. Adult patients (male and nonpregnant females, 18 years of age or older) with symptomatic cholelithiasis and an American Society of Anesthesiologist (ASA) rating of I-III scheduled to undergo elective LapChole were eligible for inclusion. LapCholes were chosen for study as they are frequently performed at WAMC as well as other large hospitals. Consequently, the procedure allowed for both timely completion of the study and broad applicability.
Patients were not considered for enrollment if their ASA rating was a IV or V; if their cholecystectomy was classified as urgent; if they were being treated for indications other than symptomatic cholelithiasis; if they had chronic pain syndrome (pain symptoms > 3 months); if they had prior abdominal operations or conversion from laparoscopic to open cholecystectomy; if they were pregnant; if they had chronic liver disease (alanine transaminase > 129 IU/mL, aspartate transaminase > 120 IU/mL) or chronic kidney disease (creatinine clearance < 30 mL/min); or if they received intraoperative nonsteroidal anti-inflammatory drug (NSAID). Additionally, patients were asked if they had taken any NSAIDS, COX 2 agents, or acetaminophen within 24 hours before the operative procedure in order to prevent possible overdosing of acetaminophen and confounding effects.
Subjects were randomly assigned to either receive two doses of 1,000 mg IVA and an oral placebo or two doses of 1,000 mg OA and IV saline. The randomization sequence was concealed from the research team until all enrolled subjects had completed the study. Only a member of the Department of Pharmacy had access to the group assignments. The allocation sequence was generated using a randomization table created by a member of the Department of Pharmacy who was not involved in direct patient care.
Materials
IVA was prepared using manufacturer's instructions [22] . IVA was administered in a 100 mL saline bag labeled "IV Acetaminophen Study"; the saline placebo was labeled the same. The OA and oral placebo had the same shape, size, and color. Subjects received one dose (1,000 mg) of acetaminophen (IV or oral) one hour prior to the operation to allow for absorption and one dose four hours after the initial dose. The saline/IVA bag was hung and administered to the subject by an anesthesiologist in the holding area. The placebo pills/OA were given to the subject by the research nurse with a small amount of water. Both routes were administered at the same time.
Perioperative, Operative, and Postoperative Procedures
All anesthetic and operative procedures were conducted at WAMC. The LapChole procedure was performed under general endotracheal anesthesia, utilizing institutional standards of practice including anesthetic premedication (benzodiazepine) within 30 minutes of the procedure and prophylactic antimicrobial delivery within 60 minutes of surgical incision. Subjects received opioid analgesic (fentanyl and/or hydromorphone) during the operation. Anesthesia was maintained via an inhaled agent. Anesthesia providers were also blinded to the subject's group assignment. The only restriction to their practice was that they were not allowed to administer acetaminophen or ketorolac.
Periumbilical access was used to establish pneumoperitoneum with a Veress needle followed by placement of a 10 mm laparoscopic camera port. At the conclusion of standard 4-port LapChole (one 10 mm, and three 5 mm operating ports) and at the time of evacuation of pneumoperitoneum, all subjects received local anesthetic infiltrated at each port site. No antibiotics were administered after the procedure.
Standard analgesia according to institutional standard of practice consisted of narcotic administration perioperatively, as well as narcotic analgesic rescue. Subjects were also administered postoperative nausea and vomiting prophylaxis with dexamethasone, ondansetron, or both. Subjects resumed oral intake within 12 hours of operation and had dietary advancement as tolerated following the procedure. Following LapChole subjects received, on their request (PRN), nonacetaminophen narcotic analgesia. Following hospital discharge, subjects were prescribed nonacetaminophen-containing oral analgesics for home use as needed and provided a pain diary to record pain ratings, pain medication use, and diary entry time every six hours after discharge, for a total of 24 hours. Diaries were returned by self-addressed, stamped mail.
Outcome Measures
Demographic variables included age, gender, race/ethnicity, ASA classification, height, and weight. Pain was self-reported by subjects using a numeric rating scale (NRS), with 0 indicating no pain and 10 indicating the worst pain imaginable. As the assessment of pain is subjective, the NRS was selected as the most appropriate method to record the primary study end point on a per-subject basis. Pain medication was recorded and converted to oral morphine equivalents (OME; mg) using the Hopkins Opioid Program [23] . NRS scores were obtained in the perioperative period (baseline), upon awakening in and exiting the postanesthesia care unit (PACU) and at home using the pain diary. OME data was obtained in the perioperative, operative, and PACU periods, as well as at home using the pain diary.
The primary outcome was the time-weighted sum of pain intensity differences from baseline over the initial 24 hours following LapChole (SPID24). Per the ClinicalTrials.gov registration, the intended primary outcome was listed simply as "pain after treatment." It was recognized that this outcome was vague. Therefore, the SPID24 was derived from NRS scores, assessment time stamps, and preoperative NRS scores, using the trapezoidal rule of the curve of change from preoperative pain levels representing the time from postoperative awakening to 24 hours postawakening. SPID24 was selected as it corrects for possible bias of higher preoperative NRS scores and subsequent larger reductions in NRS scores occurring as a result. Individual time stamps for each assessment were used to more fully refine the primary outcome and account for interindividual variation in at-home pain diary entry times. Greater (and more positive) SPID24 scores reflect lesser pain intensity experienced.
The secondary study outcomes included the summed total OME used over the 24-hour postoperative period (OME24), and the proportion of subjects reporting average postoperative NRS scores of 4 or higher (pain ! 4). NRS scores were calculated similarly to the SPID24 and derived from post-operative NRS scores and assessment time stamps using the trapezoidal rule of the curve of change from an NRS of 4.0. Positive values indicated an average postoperative pain level above the cutoff. An average NRS of 4 or higher has been identified as an optimal treatment threshold with clinical relevance in the 24-hour postoperative period, reflecting moderate pain [24] . For example, this cutoff score was associated with requiring analgesic intervention and pain-related interference with sleep, mood, and deep breaths, as well as patient satisfaction with pain treatment during the first 24 hours after surgery [24] . The examination of this binary, proportion-based variable is consistent with the recommendations regarding clinical significance in postoperative patients when average pain scores are low (e.g. when not recruiting patients with chronic pain) [25] .
Statistical Methodology
All data were analyzed with the IBM SPSS version 24 (IBM Corporation, Armonk, NY, USA). Analyses of primary and secondary outcomes were performed using an intention-to-treat (ITT) population, which included all randomized subjects who received the study drug and provided a baseline NRS score. Missing data was imputed for NRS scores. For instances in which NRS scores were missing intermittently, linear interpolation was used. Otherwise, NRS scores were imputed using the last observation carried forward (LOCF) method.
Univariate statistics assessed data normality and the presence of outliers. Bivariate tests (e.g., v 2 , MannWhitney U, independent sample t tests, Pearson and Spearman correlations) examined whether groups differed in baseline characteristics and whether baseline characteristics were significantly associated with the primary and secondary outcomes. Per recommendations in data interpretation in clinical trials for pain management [26] , two analysis of covariance (ANCOVA) tests examined whether treatment groups were significantly different in SPID24 and OME24. A binary logistic regression tested whether the probability of reporting average postoperative pain of 4 or higher was significantly different between treatment groups. Variables were considered for inclusion as covariates if values were significantly different between groups or significantly related to the primary or secondary outcomes. Including covariates helped to reduce error variance accounted for in the outcomes by extraneous variables [26] .
Sample size estimations based on 80% power and an a of 0.05, indicated the need for 80 subjects in each group, 160 subjects overall, to detect an effect size of d ¼ 0.4. Given changes in study personnel, we are unable to describe the exact origin of the calculations. Similar to a randomized controlled trial completed by Wininger and colleagues examining postlaparoscopic surgery SPID24 differences between two acetaminophen dosing regimens and a placebo, a sample size of 80 participants in each group would provide 90% power to detect a difference of 159.8 in SPID24 scores with an estimated 289.3 pooled SD and assumed 15% dropout rate (estimated effect size of d ¼ 0.55) [27] . It was recognized that due to not reaching the intended sample size, the power to achieve statistically significant differences at the stated effect size was low. Sample size was not achieved due to difficulties recruiting subjects in the allotted funding period. Per regulatory requirements, recruitment first leveraged information flyers and provider referral. After reporting significant difficulties recruiting through these methods, the regulatory board allowed research staff to directly contact potential subjects awaiting laparoscopic cholecystectomies.
In proceeding forward, the present findings are interpreted as preliminary and descriptive. Based on previous findings of SPID24 treatment group differences in randomized control trials comparing NSAIDs with placebos for postabdominal and -orthopedic operative pain, the intended sample size was powered to detect an approximately 18-(pooled standard deviation ¼ 38) [28] to approximately 27-point (pooled standard deviation ¼ 60) [29] group difference (approximately 0.75 to 1.13 average NRS score difference), and the achieved sample size could detect an approximately 38-to 44-point group difference (approximately 1.58 to 1.83 average NRS score difference). Based on previous studies, a group difference of approximately 24 points (one-point average score difference between groups) may be considered clinically meaningful when examining pain after abdominal or pelvic surgery, as well as other forms of surgery [30, 31] .
In the event the null hypothesis was retained in the ANCOVA examining the primary outcome (P > 0.05) demonstrating no statistically significant SPID24 differences between groups, post hoc analyses examined the adjusted 90% confidence intervals (CIs) of the mean group difference to determine equivalence, as indicated by whether a 24-point or greater difference between groups was possible [31] . In the event the null hypothesis was retained in the binary logistic regression examining differences in the probability of reporting average postoperative pain of 4 or higher, follow-up t tests with 90% CIs examined whether the difference in predicted probabilities between treatment groups was þ/-10%. This margin was selected based on previous research examining equivalence in pain relief success after abdominal and pelvic surgery [31] , but we note our outcome was not calculated in the same fashion. This study was not originally designed to examine equivalence, and therefore the equivalence tests are considered descriptive.
Results
A total of 126 patients were screened. Sixty-seven subjects were recruited for participation between January 2013 and June 2015 at Womack Army Medical Center (WAMC), Fort Bragg, North Carolina. Four subjects were excluded due to their operation being canceled or they became ineligible due to laboratory results and taking medications that were part of exclusionary criteria; and two subjects withdrew from the study prior to receiving the study medication dose and were also excluded from analyses. One subject received two doses of the placebo medication and therefore was not included in the analyses, as the additional dose may have impacted subsequent NRS scores relative to subjects receiving the intended dose. Ten subjects did not return their pain diaries after discharge, and PACU exit NRS score did not differ between treatment groups (U ¼ 173.00 P ¼ .11) and therefore was imputed using LOCF for the remaining time points. The ITT population included 60 subjects (Figure 1) . First, univariate statistics examined the presence of outliers and normality. One subject had an OME24 of 449.6, which was more than 4.5 SDs above the mean OME. This outlier was genuine, yet extreme, and therefore could skew analyses in favor of one treatment over the other. Therefore, the value was Winsorized using Tukey's hinges to 309.45 (2.89 SDs above the new mean). Next, bivariate tests examined whether baseline characteristics differed between groups (Table 1) or were significantly associated with the primary and secondary outcomes. The IVA group had a significantly greater proportion of males than the OA group. SPID24 was significantly correlated with age (r ¼ 0.30, P ¼ 0.02) and preoperative NRS (q ¼ 0.72, P < 0.001). OME24 was significantly correlated with operation length (q ¼ 0.34, P ¼ 0.01) and marginally correlated with age (q ¼ À5.23, P ¼ 0.098). Lastly, subjects with pain of 4 or higher were older than subjects below the threshold (t ¼ 2.72, P ¼ 0.01). Therefore, the ANCOVA examining SPID24 outcomes included gender, age, and preoperative NRS as covariates; the ANCOVA examining OME24 included gender, age, and operation length as covariates; and the binary logistic regression examining pain of 4 or higher included gender and age.
The primary outcome, SPID24, was analyzed using an ANCOVA. The effect of treatment group was nonsignificant (F(1,550 ¼ 0.39, P ¼ 0.54, partial g 2 ¼ 0.007). The IVA group had an adjusted SPID24 mean of -69.69 (90% CI ¼ À79.81 -À59.57), and the OA group had an adjusted mean of -63.96 (90% CI ¼ À74.83-À53.09). The mean difference based on adjusted means was 5.73 (90% CI ¼ À21.07-9.62). Furthermore, the mean difference based on adjust means was fewer than 24 points, and therefore fell within the range of predetermined equivalence. In the ANCOVA examining OME24, a secondary outcome, the effect of treatment group was nonsignificant (F(1,46) ¼ 0.47, P ¼ 0.50, partial g 2 ¼ 0.01). The IVA group had an adjusted OME24 mean of 151.11 (90% CI ¼ 133.30-168.92), and the OA group had an adjusted mean of 162.44 (90% CI ¼ 142.64-182.25). The mean difference based on adjusted means was 11.33 (90% CI ¼ -38.99-16.32). Lastly, in the binary logistic regression, the treatment group was not significantly associated with the probability of reporting pain of 4 or higher (b ¼ 0.24, Exp(B) ¼ 1.28, P ¼ 0.68), such that the probability of reporting pain of 4 or higher, after adjusting for covariates, was slightly higher in the OA group (53.57%) than the IVA group (46.88%), though this was not statistically significant (mean difference ¼ 6.70%, 90% CI ¼ À14.94-1.55%, t ¼ 1.36, P ¼ 0.18) (see Figure 2) . The 90% CI fell outside the þ/-10% range of equivalence.
Discussion
To our knowledge, this is the first prospective, randomized, double blind, placebo-controlled trial with administration of IVA starting in the preoperative period and comparing it directly with OA looking at clinical outcomes after elective surgery. Due to the sample size, the power to detect significant treatment differences was low, and the study was not designed nor powered to examine equivalence, therefore the findings are preliminary and descriptive. The present findings did not find statistically significant differences between the IVA and OA groups for summed pain intensity difference scores, total opioid consumption over the 24-hour postoperative period, or probability of reporting moderate postoperative pain. The 90% CI indicated that up to a 21-point SPID24 group difference was possible. This value is within the 24-point difference range of equivalence [31] . The OA group had an approximately 6.70% greater likelihood of reporting moderate postoperative pain, on average, in the 24 hours after surgery. This was not statistically significant, but examination of confidence intervals indicated that this difference may fall outside the range of equivalence.
Dosing acetaminophen at four-hour intervals was requested by the sponsor and was heavily discussed and researched among the study team. Though four-hour intervals were safe, the preferable interval would have been six hours, requiring a longer stay and bed space for subjects. Due to that decision, additional safety checks were instituted to ensure acetaminophen dose remained below 4 g in 24 hours. First, discharge medications for each subject were reviewed to ensure none contained acetaminophen. Second, subjects were then explicitly counseled to refrain from using acetaminophen-containing products for 24 hours. Furthermore, all patients with abnormal liver function were excluded from the study.
There are several limitations to this study. First, we utilized a relatively small sample size, and a larger sample would have enabled detection of smaller effects, if present. We also cannot generalize our results to chronic pain patients due their exclusion in the study. Secondly, subjects reported relatively low pain scores at baseline, as well as upon awakening in the PACU. Therefore, sensitivity to detect pain reductions was lower relative to detecting pain increases. However, pain management is relevant for patients regardless of their baseline or initial pain levels and including patients with lower initial pain levels allowed us to capture the potential of experiencing pain increases, especially when leaving the hospital and returning home. Thirdly, It may be difficult to extrapolate this data to other operative procedures, though we suspect that laparoscopic procedures, in general, impact the same type of pain receptors. Though previ- ously identified as clinically meaningful and recommended as inclusion as an outcome [24, 25] , NRS cutoff scores for postoperative pain provide gross analyses of pain management and therefore were selected as a secondary outcome to further describe the sample and treatment differences, as well as provide an additional metric for replication studies. Future analyses would benefit from examining sample-specific cutoff scores that are clinically meaningful (e.g., associated with greatest treatment satisfaction). Also, due to the nature of the study, it was not possible to verify the time or dosages taken postdischarge. Finally, PACU/hospital discharge is often cited as an important outcome in pain studies. Due to the nature of our design, subjects received a second dose of medication four hours after their first dose, thus obligating them to a PACU stay that was longer than normally required.
Future studies should focus on larger sample sizes to confirm these results, as well as include a diversity of operative procedures and patients with a range of baseline pain scores. While the route of acetaminophen may have no practical impact on pain for LapCholes, it is premature to extend these results to other procedures with possibly disparate pain modalities. Additional studies are needed to identify which patient populations would benefit from IVA as opposed to OA. Lastly, this research might be replicated for other medications with dramatically different IV and oral formulary changes in an effort to stem the rise in health care such as ibuprofen that now has an IV formulation. Ketorolac also comes in a tablet but has limited use.
As health care costs continue to rise [32] , it is incumbent on the medical community to evaluate best practices and institute cost savings at all levels. Pharmaceuticals are one of the areas of the most rapidly rising health care costs. This study provides some insight into the clinical effectiveness of IVA vs OA. The price of IVA increased in 2014, making it up to 35 times more expensive than OA [15] . In turn, hospital pharmacies must battle the demand for novel analgesic agents while weighing the cost and effectiveness of such agents. Our study suggests that patients undergoing laparoscopic cholecystectomy do not experience differential benefit in pain management or opioid consumption when receiving IVA vs OA. If replicated with a larger sample size and cost-effectiveness metrics, the preferred use of OA over IVA could result in a large cost savings for one of the most commonly performed surgeries in the country.
